GTX-102

GTX-102 is a novel, concentrated oral-mucosal spray formulation of **betamethasone**, a synthetic glucocorticoid. Developed by **Grace Therapeutics** (a subsidiary of **Acasti Pharma**), it was specifically designed to treat neurological symptoms in patients with **Ataxia Telangiectasia (A-T)**, a rare genetic disorder. The formulation allows for rapid absorption through the tongue and oral mucosa, providing a convenient administration route for pediatric populations who may have difficulty swallowing traditional oral medications. While GTX-102 demonstrated comparable bioavailability to intramuscular and oral solution forms of betamethasone in Phase 1 pharmacokinetic bridging studies, its development was deprioritized by the company in favor of other pipeline candidates, such as GTx-104.

Other names

betamethasone oral spraybetamethasone oral-mucosal spray